Alnylam Pharmaceuticals SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

SCHEDULE 13GOct. 30, 2026, 1:36 p.m. ETView on SEC.gov
10-QOct. 29, 2026, 8:20 a.m. ETView on SEC.gov
8-KOct. 29, 2026, 8:16 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedAlnylam Q3 2026 Non-GAAP Diluted EPS of $16.26 Tops $2.25 Consensus on $1.9 Billion Tax Benefit; Revenue of $1.46 Billion Beats $1.43 Billion Estimate
4Oct. 6, 2026, 4:12 p.m. ETView on SEC.gov
4Sept. 22, 2026, 4:07 p.m. ETView on SEC.gov
10-QJuly 30, 2026, 8:11 a.m. ETView on SEC.gov
8-KJuly 30, 2026, 8:06 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits